Investment Analysts’ Weekly Ratings Updates for Xencor (XNCR)

A number of firms have modified their ratings and price targets on shares of Xencor (NASDAQ: XNCR) recently:

• 11/7/2026 – Xencor was upgraded by Wall Street Zen from “hold” to “buy”.
• 11/5/2026 – Xencor is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $70.00 price target on the stock.
• 10/27/2026 – Xencor had its price target raised by Truist Financial from $29.00 to $40.00. They now have a “buy” rating on the stock.
• 10/27/2026 – Xencor had its price target raised by Wells Fargo & Company from $30.00 to $44.00. They now have an “overweight” rating on the stock.
• 10/27/2026 – Xencor had its price target raised by Royal Bank Of Canada from $20.00 to $43.00. They now have an “outperform” rating on the stock.
• 10/27/2026 – Xencor had its price target raised by Wedbush from $30.00 to $45.00. They now have an “outperform” rating on the stock.
• 10/26/2026 – Xencor was given a new $45.00 price target by Barclays. They now have an “overweight” rating on the stock.
• 10/21/2026 – Xencor had its “outperform” rating reaffirmed by Wedbush. They now have a $30.00 price target on the stock.
• 9/30/2026 – Xencor is now covered by Wells Fargo & Company. They set an “overweight” rating and a $55.00 price target on the stock.
• 9/28/2026 – Xencor had its “buy” rating reaffirmed by Truist Financial. They now have a $29.00 price target on the stock, up from $27.00.
• 9/21/2026 – Xencor had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/21/2026 – Xencor had its price target raised by Bank of America from $20.00 to $26.00. They now have a “neutral” rating on the stock.
• 9/11/2026 – Xencor had its price target raised by Barclays from $27.00 to $35.00. They now have an “overweight” rating on the stock.

Xencor Stock Up 7.9%

XNCR opened at $38.59 on Tuesday. Xencor, Inc. has a 12-month low of $10.38 and a 12-month high of $39.71. The business has a 50 day moving average of $26.42 and a 200-day moving average of $17.59. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of -24.27 and a beta of 0.78.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.83. Xencor had a negative return on equity of 21.37% and a negative net margin of 58.79%. The business had revenue of $116.52 million for the quarter, compared to analyst estimates of $63.00 million. During the same period in the previous year, the firm earned ($0.08) EPS. The firm’s revenue was up 453.3% compared to the same quarter last year. As a group, analysts expect that Xencor, Inc. will post -2.85 earnings per share for the current year.

Xencor, Inc is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target.

Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements.